Christophe Louvet - Researcher Profile

Publications

3 shown

Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer

Volker Heinemann , Stefan Boeck , Axel Hinke +2 more

The meta-analysis of randomized trials indicated a significant survival benefit when GEM was either combined with platinum analogs or fluoropyrimidines. Based on a preliminary s...

2008 BMC Cancer 425 citations

Gemcitabine in Combination With Oxaliplatin Compared With Gemcitabine Alone in Locally Advanced or Metastatic Pancreatic Cancer: Results of a GERCOR and GISCAD Phase III Trial

Christophe Louvet , Roberto Labianca , Pascal Hammel +10 more

Purpose Gemcitabine (Gem) is the standard treatment for advanced pancreatic cancer. Given the promising phase II results obtained with the Gem-oxaliplatin (GemOx) combination, w...

2005 Journal of Clinical Oncology 945 citations

Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial

Thierry Conroy , Jean-François Bosset , Pierre-Luc Etienne +54 more

2021 The Lancet Oncology 1089 citations

Frequent Co-Authors

Researcher Info

h-index: 3
Publications: 4
Citations: 3,548
Institution: Hôpital Ambroise-Paré

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0002-2240-4706

Impact Metrics

h-index 3

h-index: Number of publications with at least h citations each.